arrow
J

John Misasi

nih national institute of allergy & infectious diseases (niaid)
H指数:27
被引数:3,928

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine

针对接受17D疫苗接种者体内循环的黄热病病毒株的高效单克隆抗体

2026-01-010
PRE
Novel Lineages of SARS-CoV-2 Receptor Binding Domain Monoclonal Antibodies Demonstrate Broad and Potent Neutralization Across SARS-CoV-2 and Other Sarbecoviruses
2025-11-010
PRE
A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo
2024-10-090
PRE
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

初次暴露于SARS-CoV-2变体会引起收敛的表位特异性,免疫球蛋白V基因的使用和公共b细胞克隆

2022-12-145
OAAI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
2022-05-01281
OAAI
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
2022-02-0145
OAAI
High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19

高通量单拷贝测序揭示了SARS-CoV-2尖峰变异与急性新型冠状病毒肺炎期间体液免疫的增加一致

2021-04-0827
OAAI
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses
IMMUNITY
IF26.3
2021-04-0136
OAAI
Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

系统性埃博拉病毒疾病复发引发的埃博拉病毒传播

2021-04-0164
OAAI
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes
2020-10-0147
OAAI
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

靶向埃博拉病毒糖蛋白 (VRC 608) 的治疗性单克隆抗体mAb114的安全性,耐受性,药代动力学和免疫原性: 开放标签1期研究

LANCET
IF88.5
2019-03-01107
OAAI
Functional interrogation and mining of natively paired human VH: VL antibody repertoires
2018-01-08118
OAAI